Here s what to know about the risk of blood clots and the AstraZeneca vaccine kesq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kesq.com Daily Mail and Mail on Sunday newspapers.
Updated: 2 Apr 2021, 2:12
THIRTY cases of blood clots after having the AstraZeneca vaccine have now been reported in UK - six times the number previously known.
But officials stressed it is still safe and there was need to suspend jabs like in some European countries. Read our coronavirus live blog for the latest news & updates.
5
A health regulator says a total of 30 people have suffered blood clots in the weeks after getting the AstraZeneca jab in the UKCredit: Getty
It comes as the UK s successful jabs roll-out, as well as the tough lockdown, force down deaths
The Medicines and Healthcare products Regulatory Agency (MHRA) revealed the figures last night.
Can AstraZeneca dispel doubts about its shots?
With the company caught up in murky data releases and public relations misfires, experts worry that the world may turn its back on a vaccine that still holds promise for combating the pandemic.
ByLinda Marsa
The AstraZeneca shot was supposed to be
the vaccine for a couple of billion people. It is inexpensive at just a couple of dollars per dose and can be stored in an ordinary fridge unlike the mRNA vaccines. But after reports the shot may trigger a rare side effect, and the company’s string of communication blunders, public health officials worry that the people in some countries may have lost faith in the world’s most important vaccine.
Here s what to know about the risk of blood clots and the AstraZeneca vaccine cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.
Science s COVID-19 reporting is supported by the Heising-Simons Foundation
It s been one step forward, two back for AstraZeneca s COVID-19 vaccine. Even as the company rebutted criticism of its efficacy claims last week, a bigger problem loomed for the vaccine and the many millions depending on it. Evidence continues to accumulate that an unusual clotting disorder seen in dozens of European recipients is a real, albeit rare, side effect. A preprint has detailed a proposed mechanism, and multiple scientific groups have said the worry is legitimate and must be seriously weighed against the vaccine s COVID-19 protection.
This week, Canada and Germany joined Iceland, Sweden, Finland, and France in recommending against the vaccine s use in younger people, who seem to be at higher risk for the clotting problem and are less likely to develop severe COVID-19. The approach makes sense given that other vaccines are available, says Sandra Ciesek, a virologist at Goethe University Frankfurt.